Staphylococcal toxic shock syndrome in a child with interleukin‐17 inhibitor treatment for psoriasis
Copyright policy )Staphylococcal toxic shock syndrome in a child with interleukin‐17 inhibitor treatment for psoriasis
AbstractA 6‐year‐old girl presented with fever, skin rash, anuria, and conjunctivitis that rapidly progressed to toxic shock syndrome. Following hospital discharge, she developed a staphylococcal abscess on the lower extremity. She had recently received the first two doses of the interleukin‐17 (IL‐17) inhibitor secukinumab for resistant plaque psoriasis. IL‐17 is known to be essential in host defense against Staphylococcus aureus. To our knowledge, this is the first reported case of staphylococcal toxic shock syndrome (STSS) associated with an IL‐17 inhibitor.
Staphylococcus aureus, Interleukin-17, Humans, Psoriasis, Female, Staphylococcal Infections, Child, Shock, Septic
Staphylococcus aureus, Interleukin-17, Humans, Psoriasis, Female, Staphylococcal Infections, Child, Shock, Septic
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).7 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!